Showing results (101-110 of 1,827) with videos related to

Sort By:
Pageof 183
ESMO Open|January 7, 2025
A taxonomy of the factors contributing to the overtreatment of cancer patients at the end of life. What is the problem? Why does it happen? How can it be addressed?N I Cherny, N Nortjé, R Kelly, et al.
ESMO Open|January 8, 2025
The pathway alteration load is a pan-cancer determinant of outcome of targeted therapies: results from the Drug Rediscovery Protocol (DRUP)K Verkerk, L J Zeverijn, J van de Haar, et al.
ESMO Open|January 7, 2025
Efficacy of pembrolizumab in microsatellite-stable, tumor mutational burden-high metastatic colorectal cancer: genomic signatures and clinical outcomesK Yamaguchi, K Tsuchihashi, S Ueno, et al.
ESMO Open|January 4, 2025
Ethnic origin in cancer clinical trials: overrated or understated? A comprehensive analysis of cancer clinical trials leading to FDA and EMA approvals between 2020 and 2022H C Puhr, E C Winkler, M Preusser
ESMO Open|January 4, 2025
Comparative overall survival of CDK4/6 inhibitors plus an aromatase inhibitor in HR+/HER2- metastatic breast cancer in the US real-world settingH S Rugo, R M Layman, F Lynce, et al.
ESMO Open|January 4, 2025
Results of a patient-level pooled analysis of three studies of trastuzumab deruxtecan in HER2-positive breast cancer with active brain metastasisR Bartsch, J M Pérez-García, J Furtner, et al.
ESMO Open|December 19, 2024
Globalization of clinical trials in oncology: a worldwide quantitative analysisF Izarn, J Henry, S Besle, et al.
ESMO Open|December 1, 2024
A phase I dose escalation study of the LRP5 antagonist BI 905681 in patients with advanced and metastatic solid tumorsD R Spigel, J S Wang, L Pronk, et al.
ESMO Open|November 28, 2024
Lurbinectedin in extensive-stage small-cell lung cancer: a brief report of the IFCT-2105 LURBICLIN studyN Girard, F Guisier, A Swalduz, et al.
ESMO Open|November 5, 2024
Molecular Tumor Board of the University Medical Center Groningen (UMCG-MTB): outcome of patients with rare or complex mutational profiles receiving MTB-advised targeted therapyV D de Jager, P Plomp, M S Paats, et al.
Pageof 183